Literature DB >> 19509247

Epigenetics in cancer: targeting chromatin modifications.

Leigh Ellis1, Peter W Atadja, Ricky W Johnstone.   

Abstract

Posttranslational modifications to histones affect chromatin structure and function resulting in altered gene expression and changes in cell behavior. Aberrant gene expression and altered epigenomic patterns are major features of cancer. Epigenetic changes including histone acetylation, histone methylation, and DNA methylation are now thought to play important roles in the onset and progression of cancer in numerous tumor types. Indeed dysregulated epigenetic modifications, especially in early neoplastic development, may be just as significant as genetic mutations in driving cancer development and growth. The reversal of aberrant epigenetic changes has therefore emerged as a potential strategy for the treatment of cancer. A number of compounds targeting enzymes that regulate histone acetylation, histone methylation, and DNA methylation have been developed as epigenetic therapies, with some demonstrating efficacy in hematological malignancies and solid tumors. This review highlights the roles of epigenetic modifications to histones and DNA in tumorigenesis and emerging epigenetic therapies being developed for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509247     DOI: 10.1158/1535-7163.MCT-08-0860

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  190 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

Review 2.  Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.

Authors:  Stephanie M Tortorella; Simon G Royce; Paul V Licciardi; Tom C Karagiannis
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

Review 3.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

Review 4.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

5.  Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.

Authors:  Xue-Xi Yang; Jing-Zhe Sun; Fen-Xia Li; Ying-Song Wu; Hong-Yan Du; Wei Zhu; Xiang-Hong Li; Ming Li
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 6.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

7.  The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes.

Authors:  Yi Qing He; Elissa L Sutcliffe; Karen L Bunting; Jasmine Li; Katharine J Goodall; Ivan K A Poon; Mark D Hulett; Craig Freeman; Anjum Zafar; Russell L McInnes; Toshiki Taya; Christopher R Parish; Sudha Rao
Journal:  Transcription       Date:  2012 May-Jun

8.  Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Authors:  Shuai Gao; Jie Zang; Qianwen Gao; Xuewu Liang; Qinge Ding; Xiaoyang Li; Wenfang Xu; C James Chou; Yingjie Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-19       Impact factor: 3.641

Review 9.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

10.  The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.

Authors:  Hanieh Jafary; Shahin Ahmadian; Masoud Soleimani
Journal:  Tumour Biol       Date:  2013-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.